← All trials
NCT03479086
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2017
- Primary completion
- Nov 1, 2020
- Completion date
- Nov 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- South West Sydney Local Health DistrictLead sponsor
- University of SydneyOverall official - principal investigator
- University of SydneyCollaborator
- National Health and Medical Research Council, AustraliaCollaborator
- Macquarie UniversityOverall official - principal investigator
- South West Sydney Local Health DistrictReponsible party - principal investigator
- Sydney Local Health DistrictOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.